Mindscape Collective is now The Consciousness Library. Same library, new name. You may need to sign in again. About the change
Skip to content

Rudy Schreiber

3 papers in the library · 76 citations · publishing 2021-2023

Papers

Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach

Neurobiology of Learning and Memory May 25, 2021 Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber 49 citations

Major depressive disorder's high heterogeneity makes broad treatments difficult. Focusing on single, biologically understood core symptoms may be more viable. The Research Domain Criteria framework offers a trans-diagnostic dimensional approach. Psychedelics show potential antidepressant activity, possibly explained through multi-level analysis of cognitive systems. Cognitive deficits like negative emotional processing and negativity bias lead to depressive rumination. Psychedelics increase long-term cognitive flexibility, normalizing negativity bias and reducing rumination.

How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework.

Psychopharmacology (Berl) March 29, 2022 Manon M.j. van den Berg, Igor Magaraggia, Rudy Schreiber et al. 14 citations

A theoretical framework is proposed to distinguish the hallucinogenic effects of psychedelics from their antidepressant effects. The authors argue that hallucinations and mood improvement may arise through separable neural mechanisms, and they outline a translational approach—spanning cellular, circuit, and behavioral levels—to test this dissociation. The framework suggests that antidepressant benefits could be achieved without the hallucinatory side effects, potentially leading to safer treatments. The paper synthesizes evidence from preclinical and clinical studies to support the idea that the two phenomena are not inevitably linked, though it acknowledges that further research is needed to confirm this separation.

Examining the Psychoactive Differences between Kratom Strains

International Journal of Environmental Research and Public Health July 21, 2023 Guido Huisman, Maximilian Menke, Oliver Grundmann et al. 13 citations

Kratom, a Southeast Asian plant containing alkaloids that affect humans, is sold online in strains marketed as having distinct effects. A survey of 644 current kratom users compared self-reported effects of red, green, and white strains. Respondents reported distinct subjective experiences matching marketing claims, but independent laboratory analysis of the products found no significant differences in alkaloid content across strains. This suggests marketing narratives and anecdotal reports may disproportionately influence perceived effects. Future work should include more diverse populations and vendors, and blinded experiments could determine whether reported differences stem from placebo or other factors like minor alkaloids or terpenes.